163 related articles for article (PubMed ID: 1356363)
21. [Quality of life of schizophrenic patients and clozapine].
Raoul Y; Manesse P; Delage M
Encephale; 1997 Sep; 23 Spec No 4():12-6. PubMed ID: 9417398
[TBL] [Abstract][Full Text] [Related]
22. [Schizophrenic deficit syndrome and neurologic tolerance].
Verdoux H; Bourgeois M
Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042
[TBL] [Abstract][Full Text] [Related]
23. Antipsychotic medication in the treatment of schizophrenia.
Kane JM
Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
[TBL] [Abstract][Full Text] [Related]
24. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
Chéreau I; Gorwood P; Mouchabac S
Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
[No Abstract] [Full Text] [Related]
25. [Weight gain and clozapine].
Jalenques I; Tauveron I; Albuisson E; Audy V
Encephale; 1996 Oct; 22 Spec No 3():77-9. PubMed ID: 8954282
[No Abstract] [Full Text] [Related]
26. [What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
Müller P
Nervenarzt; 1983 Sep; 54(9):477-85. PubMed ID: 6138720
[No Abstract] [Full Text] [Related]
27. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Kopala LC; Honer WG
J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
[No Abstract] [Full Text] [Related]
28. Maintenance therapy and the natural course of schizophrenia.
Davis JM
J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
[TBL] [Abstract][Full Text] [Related]
29. Information processing and maintenance dose requirements in schizophrenia.
Marder SR; Asarnow RF; Van Putten T
Psychopharmacol Bull; 1988; 24(2):247-50. PubMed ID: 2905506
[No Abstract] [Full Text] [Related]
30. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
Levinson I; Levine S
Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
[No Abstract] [Full Text] [Related]
31. [The "neuroleptic threshold"--a review of the literature].
Abraham D; Kissling W; Lauter H
Psychiatr Prax; 1996 May; 23(3):109-16. PubMed ID: 8710999
[TBL] [Abstract][Full Text] [Related]
32. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
[No Abstract] [Full Text] [Related]
33. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
Windgassen K
Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
[No Abstract] [Full Text] [Related]
34. [Lifelong relapse prevention with antipsychotics in schizophrenia].
Hasan A; Wobrock T
Psychiatr Prax; 2010 Sep; 37(6):268-70. PubMed ID: 20803409
[No Abstract] [Full Text] [Related]
35. [Neuroleptic modification of basic schizophrenic disorders].
Heim M; Morgner J
Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
[TBL] [Abstract][Full Text] [Related]
36. [Prevention of relapse in schizophrenia is discontinued too soon. Many colleagues make this mistake!].
Seemann U; Kissling W
MMW Fortschr Med; 2000 Feb; 142(5):34-8. PubMed ID: 10715937
[TBL] [Abstract][Full Text] [Related]
37. Adjunctive clonazepam in the treatment of chronic schizophrenia.
Herrera JM; Alvarez WA; Freinhar JP; Lawson WB; Sramek JJ
Int J Psychosom; 1991; 38(1-4):17-20. PubMed ID: 1685726
[TBL] [Abstract][Full Text] [Related]
38. Risks of intermittent antipsychotic treatment in schizophrenia.
Suzuki T; Nomura K; Watanabe K
J Clin Psychiatry; 2011 Jan; 72(1):114; author reply 114-5. PubMed ID: 21272519
[No Abstract] [Full Text] [Related]
39. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
[TBL] [Abstract][Full Text] [Related]
40. Psychosocial changes in persistently psychotic schizophrenic patients after an 80% reduction of neuroleptic medication [corrected].
DeLuca A; Pittman D; Gutierrez JM; Faraone SV
J Psychosoc Nurs Ment Health Serv; 1988 Aug; 26(8):13-7. PubMed ID: 2903920
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
